Table 3.
Summary of chemoprevention in colitis-associated colorectal cancer
|
Population
|
Agent
|
Efficacy of candidate chemopreventive drugs
|
Type of study
|
||
| CAC[77] | 5-ASA | Protective factors | Meta-analysis | ||
| CAC[78] | 5-ASA | Protective factors | Meta-analysis | ||
| CAC[76] | Mesalamine; Sulfasalazine | Protective factors; No statistical effect | Meta-analysis | ||
| CAC[80] | 5-ASA | No statistical effect | Meta-analysis | ||
| CAC[81] | Mesalamine | Protective factors | Case-control study | ||
| CAC[84] | 5-ASA | Protective factors | Case-control study | ||
| GI cancer in IBD[91] | 5-ASA | Protective factors | Cohort study | ||
| CAC[79] | 5-ASA | Protective factors | Nested case-control study | ||
| CAC[87] | 5-ASA | No statistical effect | A population-based study | ||
| CAC[85] | Thiopurines | Protective factors | Meta-analysis | ||
| CAC[83] | Thiopurines | No statistical effect | Meta-analysis | ||
| CAC[84] | Thiopurines | No statistical effect | Case-control study | ||
| Advanced neoplasia in IBD1[82] | Thiopurines | Protective factors | Cohort study | ||
| CRC[88] | Immunomodulators | Anti-TNF-α agents | No statistical effect | No statistical effect | Nested case-control study |
| CRC[92] | Folic acid | No statistical effect | Meta-analysis | ||
| CRC[93] | Folic acid | No statistical effect | Meta-analysis | ||
| CAC[94] | Non-aspirin NSAIDs | No statistical effect | Meta-analysis | ||
| CRC[95] | Vitamin D | No statistical effect | Meta-analysis | ||
| Colorectal adenomas[96] | Calcium intake as a food and dairy product | Significantly decrease | Meta-analysis | ||
| CRC[93] | Calcium | No statistical effect | Meta-analysis | ||
| CAC[97] | Statin | No statistical effect | Cohort study |
1
Advanced neoplasia: including high-grade dysplasia and colorectal cancer.
ASA: Aminosalicylates; NSAIDs: Nonsteroidal anti-inflammatory drugs; CAC: Colitis-associated colorectal cancer; CRC: Colorectal cancer; IBD: Inflammatory bowel disease.